Staff Members - Benha University
Montelukast combined with intranasal mometasone furoate versus intranasal mometasone furoate; a comparative study in treatment of adenoid hypertrophy
• 2021
Publication Information
Authors
Aboubakr Elshafey Ras, Mona Hosny Hamed, Abdelrahman Ahmed Abdelalim
Keywords
Mometasone furoate
Montelukast
Adenoid hypertrophy
Nasal spray
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Objectives: To evaluate the role of combined therapy using montelukast and intranasal mometasone furoate
compared to intranasal mometasone furoate alone in treatment of adenoid hypertrophy regarding efficacy and
recurrence rate.
Methods: The study included 100 children with adenoid hypertrophy, they were randomly assigned to two
groups. Group I (50 patients) received combined therapy using montelukast and mometasone furoate nasal
spray. Group II (50 patients) received only mometasone furoate nasal spray. Patients were treated for 3 months
and observed for 3 months after stoppage of treatment. Patients were evaluated using symptoms scores,
Adenoid/Nasopharyngeal ratio and endoscopic grading of adenoid hypertrophy.
Results: After 3 months of treatment, group I showed significant better scores of main symptoms than group II;
(P = 0.001), (P = 0.019) and (P = 0.008) for rhinorrhea, mouth breathing and snoring respectively. The mean
A/N ratio was 52.8 ± 11.3 in group I better than 62.88 ± 12.10 in group II (P < 0.001). Regarding the
adenoid hypertrophy grading, significant reduction in size was found in group I in 34 (68%) patients better than
in group II in 18 (36%) patients (P = 0.001). After further 3 months of follow up, the mean A/N ratio was
58.46 ± 10.05 in group I better than 66.36 ± 10.46 in group II (P < 0.001). Recurrence occurred in 8
(23.5%) cases out of 34 improved cases in group I better than 10 (55.5%) cases out of 18 cases in group II
(P = 0.02).
Conclusion: Combining oral montelukast with intranasal mometasone in treatment of adenoid hypertrophy
provided better improvements and less recurrence in comparison with single therapy using intranasal mometasone
alone.
compared to intranasal mometasone furoate alone in treatment of adenoid hypertrophy regarding efficacy and
recurrence rate.
Methods: The study included 100 children with adenoid hypertrophy, they were randomly assigned to two
groups. Group I (50 patients) received combined therapy using montelukast and mometasone furoate nasal
spray. Group II (50 patients) received only mometasone furoate nasal spray. Patients were treated for 3 months
and observed for 3 months after stoppage of treatment. Patients were evaluated using symptoms scores,
Adenoid/Nasopharyngeal ratio and endoscopic grading of adenoid hypertrophy.
Results: After 3 months of treatment, group I showed significant better scores of main symptoms than group II;
(P = 0.001), (P = 0.019) and (P = 0.008) for rhinorrhea, mouth breathing and snoring respectively. The mean
A/N ratio was 52.8 ± 11.3 in group I better than 62.88 ± 12.10 in group II (P < 0.001). Regarding the
adenoid hypertrophy grading, significant reduction in size was found in group I in 34 (68%) patients better than
in group II in 18 (36%) patients (P = 0.001). After further 3 months of follow up, the mean A/N ratio was
58.46 ± 10.05 in group I better than 66.36 ± 10.46 in group II (P < 0.001). Recurrence occurred in 8
(23.5%) cases out of 34 improved cases in group I better than 10 (55.5%) cases out of 18 cases in group II
(P = 0.02).
Conclusion: Combining oral montelukast with intranasal mometasone in treatment of adenoid hypertrophy
provided better improvements and less recurrence in comparison with single therapy using intranasal mometasone
alone.